Von Willebrand factor is a multifaceted player in hemostasis requiring a diverse array of analytical and diagnostic approaches.

Expert Rev Hematol

Member of the Standardization Committee, Normenausschuss NA 176-08-04 AA Hämostaseologie, Deutsches Institut für Normung e.V. (DIN), Berlin, Germany.

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Von Willebrand factor (VWF) plays a crucial role in hemostasis: its interactions with endothelial matrices, platelets, and factor VIII make it a key player in both primary hemostasis and coagulation. Pathology associated with VWF spans mild to severe bleeding manifestations in the case of inherited von Willebrand disease (VWD), the most common congenital bleeding disorder, or acquired von Willebrand syndrome (AVWS). Conversely, VWF can be associated with thrombotic manifestations in situations related to inflammation, infection, or inherited or acquired ADAMTS13 defects.

Areas Covered: This review article aims to provide guidance on the use and interpretation of clinical laboratory assays available to measure VWF and other factors related to VWD. Different VWF tests can be used in different clinical settings for efficient diagnosis and patient management. Assay limitations are also addressed.

Expert Opinion: A myriad of laboratory assays, from first line to esoteric assays, exist to enable adequate diagnosis of VWD and other diseases influenced by VWF. Clinical investigations of VWF are complicated because VWF has multiple functions which variably depend on the patient's pathophysiological status. The right choice of assays is therefore critical to provide adequate diagnosis in due time and with reasonable analytical efforts.

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2025.2525458DOI Listing

Publication Analysis

Top Keywords

von willebrand
16
willebrand factor
8
vwf
8
laboratory assays
8
adequate diagnosis
8
von
4
factor multifaceted
4
multifaceted player
4
player hemostasis
4
hemostasis requiring
4

Similar Publications

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine malignancy of the skin. The cell of origin of MCC is thus far unknown and proposed cells of origin include Merkel cells, pro-/pre- or pre-B cells, epithelial stem cells, and dermal stem cells. In this study, we aimed to shed further light on the possibility that a subset of MCC tumors arise from epithelial stem cells of the skin by examining the expression of hair follicle and epidermal stem cell markers in MCC and normal human skin.

View Article and Find Full Text PDF

A novel MPLKIP-variant in three Finnish patients with non-photosensitive trichothiodystrophy type 4.

Am J Med Genet A

June 2021

The Folkhaelsan Department of Medical Genetics, The Folkhaelsan Institute of Genetics and the Department of Medical and Clinical Genetics, Medicum, University of Helsinki, Helsinki, Finland.

Article Synopsis
  • - Trichothiodystrophy is a rare genetic disorder characterized by abnormal hair development and affects multiple body systems; this study focuses on two Finnish families with this condition.
  • - The researchers identified a new mutation in the MPLKIP gene through whole-exome sequencing, confirming the diagnosis of non-photosensitive trichothiodystrophy type 4 (TTD4) in three patients.
  • - This report enhances understanding of TTD4 by detailing the patients' unique physical traits and comparing their clinical features with previously documented cases.
View Article and Find Full Text PDF
Article Synopsis
  • A study looked at a treatment called L4-DRG stimulation for patients with a painful condition called CRPS.
  • The researchers tested how patients felt different sensations like pain and touch before and after 3 months of treatment.
  • They found that the treatment helped reduce pain for the patients, but it did not change how they felt warmth or touch.
View Article and Find Full Text PDF

Oral Platelet-Derived Growth Factor and Vascular Endothelial Growth Factor Inhibitor Sunitinib Prevents Chronic Allograft Injury in Experimental Kidney Transplantation Model.

Transplantation

January 2016

1 Transplantation Laboratory, University of Helsinki, Helsinki, Finland. 2 Department of surgery, Oulu University Central Hospital, Oulu, Finland. 3 Transplantation and Liver Surgery Unit, Helsinki University Central Hospital, Helsinki, Finland. 4 Division of Nephrology, Department of Medicine, Hels

Article Synopsis
  • Increased expression of PDGF and VEGF is linked to chronic rejection in kidney transplants, which can lead to allograft loss.
  • Sunitinib, a tyrosine kinase inhibitor, was tested in a rat model and shown to significantly reduce neointimal formation, smooth muscle cell activity, and chronic rejection signs while improving kidney function.
  • The findings suggest that targeting both PDGF and VEGF with sunitinib may offer a promising new approach for preventing chronic rejection in kidney transplant patients.
View Article and Find Full Text PDF